You are here

New Study of Abiraterone Suggests Using It Earlier in Prostate Cancer Treatment Cycle

J&J tested Zytiga with prednisone in a trial of 1,088 men with prostate cancer who hadn't received chemotherapy, comparing it with prednisone plus a placebo. The study began in 2009 and was due to finish in 2014, according to a government database of clinical trials.

But J&J said Thursday that an independent data monitoring committee recommended releasing results sooner than planned because an interim analysis showed "evidence of clinical benefit as well as continued evidence of favorable safety."

J&J said the interim analysis showed differences between Zytiga and placebo in two key goals for the trial: radiographic progression-free survival and overall survival.

Read the full article in the Wall Street Journal.

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs